www.youtube.com/watch?v=DQC4I8mU0v0

Read more from the original source:
Biology 1A – Lecture 8: Regulation of Enzymatic Activity – Video

Originally posted here:
Quantum biology and Ockham's razor

www.youtube.com/watch?v=pDqNnmxe2EI

Continued here:
Plant and Microbial Biology 160 – Lecture 8 – Video

www.youtube.com/watch?v=QnQe0xW_JY4

Read more:
That’s Why Carbon Is A Tramp – Video

See the original post:
Two top universities join hands to offer new degree courses

Read the rest here:
Why do cells age? Discovery of extremely long-lived proteins may provide insight into cell aging and neurodegenerative …

See more here:
Lafayette Jeff biology teacher 'blown away' by nomination

www.youtube.com/watch?v=8fAxi6MYLgs

See the rest here:
Biology at Webster University – Video

See the article here:
Report: CMU biology department sees growth, chairman believes med school had impact

REDWOOD CITY, Calif., Feb. 3, 2012 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX – News) today announced results from a large clinical study in prostate cancer evaluating the relationship of microRNAs, a novel class of biomarkers, to clinical outcomes for patients with early-stage prostate cancer. The data, presented at the 2012 Genitourinary (GU) Cancers Symposium, contribute to a greater understanding of prostate cancer biology by assessing the ability of specific microRNAs and genes to predict aggressive disease as part of the company's prostate cancer research and development program.

“In addition to supporting our development of a genomic prostate cancer assay to improve discrimination of clinically significant from insignificant prostate cancer, this study also demonstrates our innovative approach to provide a more comprehensive evaluation of biomarkers in the context of the known tumor heterogeneity of prostate cancer, one of the critical challenges faced by a biopsy-based clinical test for prostate cancer,” said Steven Shak, M.D., chief medical officer of Genomic Health. ”We remain committed to conducting multiple, well-designed prostate cancer studies in order to expand scientific knowledge about the disease and help physicians deliver better outcomes for their patients.”

In the research presented at the 2012 GU Cancers Symposium, investigators analyzed 416 prostate cancers from patients treated with radical prostatectomy (RP) at Cleveland Clinic between 1987 and 2004. Modified RT-PCR methodology was used to assess 76 microRNAs, a distinct class of biological regulators that are very small, averaging about 22 nucleotides in length.

Dr. Klein and the Cleveland Clinic have also recently completed a study evaluating whether the expression of key genes and gene groups previously identified in radical prostatectomy specimens can be similarly predictive of aggressive prostate cancer when assessed in the small tissue volumes found in prostate needle biopsies. These results are planned for presentation at the 2012 American Association of Genitourinary Surgeons meeting in April.

“Treatment decisions for men with localized prostate cancer could be improved with more accurate knowledge at the time of diagnosis for the individual patient, including likelihood of favorable features such as low grade, organ-confined disease or low probability of tumor recurrence,” said Eric Klein, M.D., chairman of the Glickman Urological and Kidney Institute at Cleveland Clinic. “These results advance our knowledge about prostate cancer and contribute to a broader effort aimed at the development of an actionable and validated genomic test that could arm physicians with additional information to help inform the patient care plan and allow us to avoid overtreatment of clinically insignificant cancers.”

Separately, Genomic Health has initiated a clinical validation study for its prostate cancer test and plans to announce topline results later this year. The ongoing clinical validation study, being performed in collaboration with leading prostate cancer researchers at the University of California, San Francisco (UCSF), is designed to determine if a multi-gene test can help patients with early stage prostate cancer by distinguishing aggressive disease requiring immediate treatment, such as surgery, from indolent disease which may be appropriately managed with active surveillance. The study will utilize Genomic Health's proprietary RT-PCR process for analyzing very small amounts of formalin-fixed paraffin-embedded (FFPE) prostate tissue obtained by diagnostic prostate needle biopsy. If positive, the clinical validation study results are expected to support the launch of the Oncotype DX® prostate cancer test in 2013.

“Identification of Prostate Cancer-Expressed MicroRNAs Associated with Clinical Recurrence (cR) and Prostate Cancer Specific Survival (PCSS) Following Radical Prostatectomy (RP)” (Abstract #21) was presented during the general poster session on Feb. 2.

Three leading medical specialty societies co-sponsor the three-day, multidisciplinary symposium, including the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO).

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX – News) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to the predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigene expression test developed for the assessment of risk of recurrence in patients with stage II disease. As of December 31, 2011, more than 10,000 physicians in over 65 countries had ordered more than 265,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org. 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical utility of microRNA's as biomarkers for early stage prostate cancer; our ability to generate similar results in further studies; our ability to develop and launch a test for prostate cancer in 2013; the ability of any tests the company may develop to optimize cancer treatment; the scope, success or results of clinical trials and the timing of such activities; the applicability of clinical study results to actual outcomes; the ability of the company's tests to impact clinical practice and; the ability of the company to successfully commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risk that study results may not be replicated in future studies; the applicability of clinical study results to actual outcomes; the risks associated with market expansion and the commercialization of current and future products; the risks and uncertainties associated with possible additional regulation of our tests both in the United States and abroad; the risks associated with competition; the risks that our products may infringe the intellectual property of third parties; the risks and potential delays associated with such studies; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

View original post here:
Genomic Health Presents Results Furthering Understanding of Biology of Prostate Cancer at the 2012 Genitourinary …

Two Texas Tech biology students, Wail Amor, a doctoral student from Lubbock, and Ann Marie Scott, a junior cell and molecular biology major placed first and second, respectively at the annual America Society for Microbiology, Texas Branch meeting.

The students received the awards for their poster presentations.

Both are students with the Tech Honors College and the Howard Hughes Medical Institute undergraduate research program. They also do lab work with their mentor, Abdul Hamood.

“Both Wail and Ann Marie are hard working individuals,” Hamood said in a statement. “They are very dedicated to their projects.”

Visit link:
Biology student earns top score at competition

See the article here:
Biology, health departments concerned with university collaboration over CMED

View original post here:
Sharon Phillips named Oklahoma Outstanding Biology Teacher 2011

View post:
Bogus biology teacher faked qualifications and worked as chief examiner for an A-Level board

www.youtube.com/watch?v=y7bxMEBcZlc

Read the rest here:
Biology 1A – Lecture 6: Cellular metabolism and catalysts – Video

HuffPost's QuickRead…

Loading…

HuffPost's QuickRead…

EDITION: U.S. CA Canada FR France US United States UK United Kingdom Animals PETA Climate Change Baby Animals Smarter Ideas More Log in | Sign Out February 1, 2012 Like

87k

  CONNECT     FRONT PAGE U.S. UK CANADA FRANCE POLITICS 2012 BLOG HUFFPOST HILL 2012 ELECTIONS FUNDRACE GREEN POLLSTER SPECULATRON OFF THE BUS BUSINESS SMALL BUSINESS ENTERTAINMENT CELEBRITY ENTERTAINMENT MUSIC RADIO MOVIES TV GAMES COMEDY TECH TECH TECHCRUNCH JOYSTIQ SCIENCE ENGADGET APPLE BLOG MEDIA LIFE & STYLE STYLE NEWS STYLELIST FOOD NEWS WEDDINGS PARENTS GREEN TRAVEL STYLELIST HOME KITCHEN DAILY DIVORCE HUFF/POST50 RELIGION CULTURE ARTS PARENTS TRAVEL COLLEGE RELIGION IMPACT BOOKS EDUCATION COMEDY HEALTHY LIVING HEALTH AND FITNESS HEALTH NEWS MINDFUL LIVING SLEEP WOMEN HEALTHY LIVING PARENTS LOCAL NEW YORK SAN FRANCISCO DENVER MIAMI PATCH CHICAGO LOS ANGELES DC DETROIT YELLOW PAGES MORE GOOD NEWS SCIENCE BLACKVOICES SPORTS WORLD GAY VOICES GREEN LATINOVOICES COLLEGE CRIME WEIRD NEWS HIGH SCHOOL GREEN ENERGY CLIMATE CHANGE ANIMALS GREEN TECH POLITICS FOOD GREEN HOLIDAY

See the rest here:
Maned Wolf Pups Born At Smithsonian Conservation Biology Institute (PHOTO)

www.youtube.com/watch?v=P75bWdU_RSY

More here:
Biology 1B – Lecture 6: Cells, Tissues – Video

High school test scores in biology went up in the Alamance-Burlington School System during the first half of 2011-12, while declining slightly in English and Algebra I compared to the first half of 2010-11.

The percentage of students achieving what the state considers proficiency in biology was 86.2 percent in the fall, up from 79.1 a year earlier.

The percentage of students achieving proficiency in English was 81.6 percent, down less than a percentage point from 82.1 percent a year earlier.

In Algebra I, 65.3 percent of students achieved proficiency in Algebra I, compared to 66.4 percent a year earlier. Neither of those figures includes the performance of eighth-grade students who take the test at the end of the year.

Dain Butler, the system’s director of accountability and school improvement, said the test scores are preliminary and are likely to change a little as results of re-tests continue to be added. But “it’s a close representation” of what final results will be, he said. Butler also warned against drawing too many conclusions about student progress before scores from the second half of the year are available in June.

Butler reviewed the information with the Alamance-Burlington Board of Education during a Monday night meeting. He said it’s hard to say why biology results improved while scores in the other two areas dipped slightly. He did say the state’s elimination of some end-of-grade tests means educators have more time to focus on the remaining subjects.

Board member Patsy Simpson said she wants to get more information about what efforts take place at schools when the percentage of students reaching proficiency in a subject is far lower than the system average.

“Be very specific,” she said.

Here are the results broken down by high school:

Cummings High School: In Algebra I, 58.2 percent of students were proficient, up from 56.5 percent.  In biology, 79.4 percent were proficient, up from 66.7 percent. In English, 68.2 percent were proficient, down from 80.4 percent.

Eastern Alamance High School: In Algebra I, 81.9 percent of students were proficient, down from 82.6 percent. In biology, 91.5 percent were proficient, up from 76 percent. In English, 79.8 percent were proficient, down from 81.8 percent.

Graham High School: In Algebra I, 54.7 percent of students were proficient, down from 60.8 percent. In biology, 90 percent of students were proficient, up from 77.9 percent. In English, 79.6 percent were proficient, down from 82.4 percent.

Southern High School: In Algebra I, 62.6 percent of students were proficient, down from 69.9 percent. In biology, 88.5 percent were proficient, up from 83.5 percent. In English, 86.6 percent were proficient, up from 79.9 percent.

Western Alamance High School: In Algebra I, 88.3 percent of students were proficient, up from 84.3 percent. In biology, 95 percent of students were proficient, up from 92.9 percent. In English, 89.7 percent were proficient, up from 88.3 percent.

Williams High School: In Algebra I, 62.2 percent of students were proficient, up from 50.4 percent. In biology, 72.3 percent were proficient, down from 73.8 percent. In English, 86.9 were proficient, up from 83.3 percent.

Read the rest here:
Test scores up in biology, down slightly in English, Algebra I

The International Society for Computational Biology (ISCB) has awarded its Overton Prize for outstanding accomplishment to Ziv Bar-Joseph, associate professor in Carnegie Mellon University's Lane Center for Computational Biology and Machine Learning Department.

The Overton Prize is awarded annually to an early- to mid-career scientist who has made a significant contribution to the field of computational biology. In recognition of the award, Bar-Joseph will give a keynote address this July at the annual International Conference on Intelligent Systems for Molecular Biology in Long Beach, Calif.

Bar-Joseph, who joined CMU's School of Computer Science (SCS) faculty in 2003, applies machine learning, statistical algorithms and signal processing techniques to the analysis of high-throughput biological data. He has led international research efforts that have identified genes important to human cell division, including a subset associated with cancer cells, which have uncovered new insights into gene regulatory networks.

In a study published last year in the journal Science, he and his colleagues observed methods that have evolved to organize cells during nervous system development. The same methods, they concluded, could be used to improve the deployment of wireless sensor networks and other distributed computing applications.

“It's stunning how he is able to handle such a diverse set of technical methods,” said Burkhard Rost, president of the ISCB. “He's a perfect example of a new generation of scientists.”

Alfonso Valencia, chair of the ISCB Awards Committee, added that the committee members were impressed not only by the quality of Bar-Joseph's scientific contribution, but by the novelty of the approaches he has developed.

“I am very pleased that Ziv has been chosen for this very richly deserved honor,” said Robert F. Murphy, director of SCS's Lane Center for Computational Biology. “Ziv's work represents an outstanding example of computational biology research: the use of novel and appropriate machine learning methods in deep collaborations with accomplished experimental biologists to yield significant biological results.”

Source: Carnegie Mellon University

Continued here:
ISCB honors CMU professor with Overton Prize